Gujarat Inject Q1 net profit jumps to ₹125.16 lakh on solar trading
Revenue rises five-fold to ₹1,245.45 lakh; strong solar module trading continues. But the nano-cap pharma company faces a leadership void after recent deaths.
— 8 earlier stories on Gujarat Inject (Kerala) Ltd. →What's new
- Net profit rises to ₹125.16 lakh from ₹7.35 lakh a year ago
- Revenue jumps five-fold to ₹1,245.45 lakh on solar module trading
- Board approves unaudited results with auditors' limited review
Why this matters
The earnings surge is real but comes off a tiny base. The solar pivot is working, yet the company still trades at a P/E of 99 and recently lost its chairman, CFO, and whole-time director in a single event. The leadership vacuum and tiny base mean these numbers must be sustained before they matter.
What we're watching
- Whether solar module trading volumes can sustain this pace
- Any update on permanent leadership after chairman's death
- The company's ability to manage rapid scale-up without debt
The full read
Gujarat Inject (Kerala) has reported a quarter that looks impressive at first glance. Net profit jumped to ₹125.16 lakh from ₹7.35 lakh a year ago, while revenue rose five-fold to ₹1,245.45 lakh on strong solar module trading. But the base is tiny, and the company's trailing P/E of 99 already reflects high expectations. More worrying: the nano-cap firm recently lost its chairman, CFO, and whole-time director in a single event, and the new MD comes from plastics, not pharma or solar. The solar trading pivot is real, but the leadership vacuum and tiny base mean this profit surge could be a one-off. The next quarter will test whether it is a trend or a spike.
Questions answered
- What drove Gujarat Inject's massive profit jump?
- Revenue from operations surged five-fold to ₹1,245.45 lakh, driven by strong solar module trading volumes. Net profit expanded to ₹125.16 lakh from ₹7.35 lakh a year ago.
- Is this profit level sustainable?
- The numbers come off a very low base and the company has a high trailing P/E of 99 and a low ROE of 1.0%. Analyst commentary suggests the results were notable but not unexpected, implying the market may have priced in the growth.
- What is the company's market cap?
- Gujarat Inject (Kerala) Ltd has a market capitalisation of approximately ₹180 crore, classifying it as a nano-cap stock.
- What about the company's leadership situation?
- In June 2026, the company lost its chairman, CFO, and whole-time director in a single death. A new managing director with a plastics background was appointed in early July, but the leadership vacuum remains a concern.
- Is Gujarat Inject still a pharmaceutical company?
- The company is classified in the pharmaceuticals sector, but its recent revenue growth is entirely from solar module trading, indicating a strategic shift in business focus.
- What was the auditor's opinion on these results?
- The board took the auditors' limited review report on record. A limited review is less comprehensive than a full audit, so investors should await the annual audited numbers for more assurance.
Gujarat Inject (Kerala) Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on GUJINJEC →- 15 Jul 2026 · 10:07 AM IST Gujarat Inject Q1 net profit jumps to ₹125.16 lakh on solar trading
- 7d ago Gujarat Inject Q1 net profit rises to ₹1.25 crore on solar trading
- 7d ago Gujarat Inject Q1 net profit jumps to ₹125.16 lakh on solar module trading
- 16d ago Gujarat Inject fills top post after chairman's death, but new MD is from plastics
- 28d ago Gujarat Inject loses Chairman, CFO & Whole-Time Director in single death